Longer transplant waits for HCC patients may be beneficial

December 2013
Hem/Onc Today;12/10/2013, Vol. 14 Issue 23, p23
The article discusses a research study which suggested the benefit of longer transplant waits for patients with hepatocellular carcinoma (HCC), presented at The Liver Meeting held in Washington on November 1-5, 2013.


Related Articles

  • Efficacy and Feasibility of Salvage Living Donor Liver Transplantation after Initial Liver Resection in Patients with Hepatocellular Carcinoma. abe, Tomoyuki; Tashiro, Hirotaka; Teraoka, Yoshifumi; Hattori, Minoru; Tanimine, Naoki; Kuroda, Shintaro; Tahara, Hiroyuki; Ohira, Masahiro; Tanaka, Yuka; Kobayashi, Tsuyoshi; Ide, Kentaro; Ishiyama, Kohei; Ohdan, Hideki // Digestive Surgery;Feb2016, Vol. 33 Issue 1, p8 

    Background/Aims: Liver transplantation (LT) is promising method of treatment for hepatocellular carcinoma (HCC) patients, but is limited by donor organ shortages and tumor progression during long wait periods. This study investigated the efficacy of salvage living donor LT (LDLT) after initial...

  • Importance of Screening for Esophagogastric Varices in Naïve Hepatocellular Carcinoma Patients within Milan Criteria: Indicator for Liver Transplantation. Kawakami, Takamasa; Hiraoka, atsushi; Michitaka, Kojiro; Ninomiya, Tomoyuki; Hirooka, Masashi; Hiasa, Yoichi // Digestive Surgery;Aug2017, Vol. 34 Issue 5, p429 

    Background/Aims: Patients with hepatocellular carcinoma (HCC) beyond Milan criteria (MC) are not eligible for liver transplantation (LT). To elucidate prognostic factors significantly linked to recurrence beyond MC or death related to the liver, we evaluated the clinical features in a series of...

  • Long-term experience with liver transplantation for hepatocellular carcinoma. Tsoulfas, Georgios; Kawai, Tatsuo; Elias, Nahel; Ko, S.; Agorastou, Polyxeni; Cosimi, A.; Hertl, Martin // Journal of Gastroenterology;Feb2011, Vol. 46 Issue 2, p249 

    Background: The effect of the model for end-stage liver disease (MELD) system on the post-transplant survival of patients with hepatocellular carcinoma (HCC) has not been fully elucidated. Our objective is to review the results of liver transplantation (LT) for HCC at the Massachusetts General...

  • Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? Saidi, R. F.; Li, Y.; Shah, S. A.; Jabbour, N. // International Journal of Organ Transplantation Medicine;2013, Vol. 4 Issue 4, p137 

    Background: Live-donor liver transplantation (LDLT) is a valuable option for patients with hepatocellular carcinoma (HCC) as compared with deceased-donor liver transplantation (DDLT); the tumor could be eradicated early. Methods: Herein, we reviewed the outcome of adult patients with HCC who...

  • Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study. Hoyos, Sergio; Escobar, Jorge; Cardona, Doris; Guzmán, Carlos; Mena, Álvaro; Osorio, Germán; Pérez, Camilo; Restrepo, Juan C.; Correa, Gonzalo // Annals of Hepatology: Official Journal of the Mexican Associatio;Jan/Feb2015, Vol. 14 Issue 1, p58 

    Introduction. Hepatocellular carcinoma is the most common primary tumor of the liver and is diagnosed in more than a half million people worldwide each year. This study aims to assess factors associated with the recurrence and survival of patients with hepatocellular carcinoma and liver...

  • Immediate Radical Therapy or Conservative Treatments When Meeting the Milan Criteria for Advanced HCC Patients After Successful TACE. Jiang, L.; Lei, J.; Wang, W.; Yan, L.; Li, B.; Wen, T.; Xu, M.; Yang, J.; Wei, Y. // Journal of Gastrointestinal Surgery;Jun2014, Vol. 18 Issue 6, p1125 

    Background and aims: Many advanced hepatocellular carcinoma (HCC) cases can be successfully downstaged into the Milan criteria; however, immediate radical therapy cannot be applied to all such patients for various reasons. Of the patients who are not eligible for immediate radical therapy, some...

  • Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. VINCENZI, UNO; SANTINI, DANIELE; RUSSO, ANTONIO; ADDEO, RAFFAELE; GIULIANI, FRANCESCO; MONTELLA, LILIANA; RIZZO, SERGIO; VENDITTI, OLGA; FREZZA, ANNA MARIA; CARAGLIA, MICHELE; COLUCCI, GIUSEPPE; PRETE, SALVATORE DEL; TONINI, GIUSEPPE // Oncologist;Jan2010, Vol. 15 Issue 1, p85 

    Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the...

  • Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience. Pusen Wang; Chunguang Wang; Hao Li; Baojie Shi; Jianning Wang; Lin Zhong // OncoTargets & Therapy;Dec2015, Vol. 8, p3775 

    Background: Liver transplantation (LT) offers the most effective treatment for hepatocellular carcinoma patients. Various preoperative variables are correlated with survival after LT, but the prognostic role of aging on LT remains controversial. Methods: Between January 2001 and December 2011,...

  • Liver transplantation for advanced hepatocellular carcinoma in patients with Child-Pugh A and B. Hammad, Ahmed; Kaido, Toshimi; Ogawa, Kohei; Fujimoto, Yasuhiro; Uemura, Tadahiro; Mori, Akira; Hatano, Etsuro; Okajima, Hideaki; Uemoto, Shinji // Surgery Today;Feb2016, Vol. 46 Issue 2, p248 

    Purpose: To investigate the outcomes of living donor liver transplantation for advanced hepatocellular carcinoma in Child-Pugh A/B patients and the usefulness of our expanded selection criteria, the Kyoto criteria. Methods: A total of 82 recipients with a Child-Pugh class A ( n = 27) or B ( n =...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics